How the analysis was instigated, and information about Cancer52 and the National Cancer Research Institute (NCRI).

A summary of the process to collate the data for this analysis, along with the classification systems used.

A look at published evidence examining the mortality and wider societal burden of cancer types.

Spend by research area in rare and less common cancers (NCRI and Cancer52 members combined) against spend in the most common cancers; breast, lung, prostate and bowel. 

Combining Cancer52 members with NCRI partners to provide a more complete picture of research spend in rare and less common cancers.

Spend by Cancer52 members looked at separately from NCRI partners.

Spend by Cancer52 members and combined spend with NCRI partners was broken down into regional spend by the principal investigator (PI) institution.

How the pandemic affected research spend and possible implications for the future.

Overall conclusions of the analysis and reflections on the data.

List of participating members and acknowlegements.